Publications by authors named "S Chandana"
Article Synopsis
- * In the trial with 30 patients, the results showed a median progression-free survival of 4.1 months and an overall survival of 7.4 months, though the primary survival endpoint was not achieved.
- * Most patients tolerated the treatment well, with a notable 24-month survival rate of 23.3%, which was higher than previously reported for this combination.
Aim: We report a unique finding of iris nodules in a woman with endogenous endophthalmitis due to with no history of ocular surgery or trauma and good visual outcome.
Materials & Methods: Retrospective case report.
Results: A 39-year-old woman with a history of type 2 diabetes mellitus presented with a decrease in vision in the right eye of 1-month duration.
Engagement of programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can interfere with the CD28 signaling requisite for T-cell activation. While immune checkpoint inhibitors (ICIs) can relieve this suppression, they are unable to drive CD28 costimulation that may mechanistically contribute to ICI resistance. Thus, CD28 costimulation in the context of checkpoint inhibition may activate immunosuppressed T-cells in the tumor microenvironment.
View Article and Find Full Text PDFIntroduction: Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible and allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC).
Methods: In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, and germline-controlled ctDNA levels were quantified and analyzed in patients with PDAC. Plasma samples (n = 1329) from 298 clinically validated patients were collected at diagnosis, perioperatively (MRD-window; within 2-12 weeks after surgery, before therapy), and during surveillance (>12 weeks post-surgery if no ACT or starting 4 weeks post-ACT) from November 2019 to March 2023.